All news from Anaesthesiology

Novel Process to produce Cell-sized Lipid Vesicles Introduced

Researchers demonstrated a novel process to produce cell-sized lipid vesicles (CLVs) from microfluidically generated double emulsion templates by investigating the interfacial parameters that control double emulsion stability for storage, and their subsequent dewetting to form multisomes or GUVs (subsets of CLVs). A report detailing this latest development was published in the journal TECHNOLOGY.

New Mechanism To Stop The Growth Of Malignant Melanoma

In this study, researchers have succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes responsible for erasing epigenetic marks at the DNA. This discovery has potential for use in future combination therapies. The study is published in the journal Cancer Cell.

Active and Passive Smoke Exposure in Urban Adolescents

Many adolescents are exposed to tobacco smoke, from either active smoking (CS) or secondhand smoke (SHS) exposure. Tobacco-specific biomarkers of exposure include cotinine (detects use in past 2–4 days) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL; detects use for a month or longer).

NNAL is expected to detect more intermittent tobacco exposure. Researchers compared NNAL and cotinine as biomarkers of exposure to tobacco in urban adolescents and determined the optimal NNAL cutoff point to distinguish CS from SHS exposure.

PharmaMar licenses Fully Synthetic Marine-Derived Payloads to Seattle Genetics

PharmaMar (MSE: PHM) has announced today the signing of an exclusive licensing agreement with Seattle Genetics Inc. (SGEN: NASDAQ GS) for fully synthetic marine-derived payloads for use in drug conjugates.

Under which Seattle Genetics receives exclusive worldwide rights to certain PharmaMar proprietary molecules for the development, manufacture, and commercialization of antibody-drug conjugates and/or other drug conjugates incorporating PharmaMar payloads.

Evaluate Hemodynamic Interventions Improves Survival in Adults With Sepsis

The Severe Sepsis and Septic Shock Early Management Bundle (SEP-1), the sepsis performance measure introduced by the Centers for Medicare & Medicaid Services (CMS), requires up to 5 hemodynamic interventions, as many as 141 tasks, and 3 hours to document for a single patient. To evaluate whether moderate- or high-level evidence shows that use of SEP-1 or its hemodynamic interventions improves survival in adults with sepsis.